Journal article
Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care
Cleveland Clinic journal of medicine, Vol.91(6), pp.361-371
06/03/2024
DOI: 10.3949/ccjm.91a.23079
PMID: 38830701
Abstract
An estimated 1.2 million people in the United States have human immunodeficiency virus (HIV) infection per US Centers for Disease Control and Prevention 2021 data. The highest risk of HIV transmission occurs during injection drug use with needle sharing and during sexual activity, most significantly in condomless, receptive anal intercourse. Preexposure prophylaxis (PrEP) for the prevention of HIV infection is part of a larger biobehavioral strategy that uses antiretroviral medication, an oral formulation taken daily or during anticipated exposure events, or an injectable formulation administered every 8 weeks. PrEP consists of 3 possible regimens: emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, or injectable cabotegravir. Primary care clinicians are strategically positioned to provide PrEP education and access.
Details
- Title: Subtitle
- Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care
- Creators
- Amy L Wiser - Cascade (United States)
- Resource Type
- Journal article
- Publication Details
- Cleveland Clinic journal of medicine, Vol.91(6), pp.361-371
- DOI
- 10.3949/ccjm.91a.23079
- PMID
- 38830701
- NLM abbreviation
- Cleve Clin J Med
- ISSN
- 0891-1150
- eISSN
- 1939-2869
- Language
- English
- Date published
- 06/03/2024
- Academic Unit
- Family and Community Medicine
- Record Identifier
- 9985134037302771
Metrics
1 Record Views